MENU

Fox Chase Cancer Center News

December 1, 2017

Patients with HIV-Associated Lymphoma Can Safely Continue Anti-Retroviral Therapy During Chemotherapy

PHILADELPHIA (December 1, 2017) – HIV patients who are treated with combination anti-retroviral therapy (cART) can safely undergo chemotherapy to treat associated lymphomas at the same time, researchers from the AIDS Malignancy Consortium, including Fox Chase Cancer Center have found.

November 28, 2017

Health Insurance Marketplace Open Enrollment Events

Saturday December 2nd and Thursday December 7th, 2017.

Suraj Peri, PhD, assistant research professor at Fox Chase, and lead author of the study
November 26, 2017

Newly Identified Laryngeal Cancer Subtypes Can Help Determine Treatment Options

PHILADELPHIA (November 24, 2017)Researchers at Fox Chase Cancer Center and the Johns Hopkins University School of Medicine have identified two new subtypes of laryngeal cancer, each of which indicates different survival outcomes for patients. These findings, which for the first time linked better survival to mutations damaging the genes NSD1 and NSD2, were validated in an independent cohort of patients treated at Fox Chase and Johns Hopkins.

November 21, 2017

Free Cancer Screening Event for Veterans

PHILADELPHIA (November 21, 2017) — The screening will be held at American Legion Post #366, 7976 Oxford Ave, on Wednesday November 29, 2017. Doors will open at 5:30 p.m. and Fundakowski and staff will provide the screenings.

Jonathan Chernoff, MD, PhD
November 20, 2017

Jonathan Chernoff of Fox Chase Cancer Center Named AAAS 2017 Fellow

Washington DC (November 20, 2017) — Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. This year 396 members have been awarded this honor because of their scientifically or socially distinguished efforts to advance science or its applications.

Nestor F. Esnaola, MD, MPH
November 9, 2017

Significant Underuse of Critical Post-Diagnosis Genetic Test Among Colorectal Cancer Patients

PHILADELPHIA (November 9, 2017) – Although it is recommended for all colorectal cancer patients, most are not being screened for a common genetic syndrome that increases the risk of several forms of cancer and can influence treatment outcomes, according to a new study in JAMA Oncology. In the largest U.S. study of its kind, researchers at Fox Chase Cancer Center found that only 28 percent of adult colorectal cancer patients undergoing colorectal cancer resection were reported to have MMR deficiency testing performed on their tumors.

Igor Astsaturov, MD, PhD
November 1, 2017

Fox Chase Cancer Center Seeks to Raise Awareness of Pancreatic Cancer

PHILADELPHIA (November 1, 2017) – November is Pancreatic Cancer Awareness month, and Fox Chase Cancer Center remains steadfast in its commitment to pancreatic cancer research. The creation of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center will significantly accelerate the pace of pancreatic cancer research, and its impact will be felt regionally and nationally.

Joan Font-Burgada, PhD
October 27, 2017

A Piece of Your Genome Might Predict Your Cancer Risk

PHILADELPHIA (October 26, 2017) – Researchers at Fox Chase Cancer Center and University of California San Diego School of Medicine have published a seminal paper in Cell that outlines characteristics on the cell’s surface that could predict the mutated oncogenes that will be present in a patient’s cancer. Major Histocompatibility Complex class I (MHC-I) displays peptides from inside on the cell’s surface, which allows T-cells to detect foreign or mutated peptides that exist inside cells.

Pages

Connect with Fox Chase